BioVersys AG

BioVersys AG is a pioneering Swiss pharmaceutical company listed on the SIX (BIOV), dedicated to innovative biotechnology research. BioVersys AG specializes in the research and development of small molecules targeting novel bacterial targets, offering crucial solutions in antimicrobial resistance (AMR) and targeted microbiome modulation. With two advanced in-house technology platforms—TRIC and Ansamycin chemistry—BioVersys is at the forefront of developing novel antibacterial drugs that overcome resistance and modulate the microbiome.

BioVersys addresses critical unmet medical needs by creating groundbreaking treatments for life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company's leading research and development programs target nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ready) and tuberculosis (Alpibectir, Phase 2), pursued in collaboration with GSK and a consortium from the University of Lille. BioVersys AG is located in the TechPark at Hochbergerstrasse 60c, 4057 Basel, a thriving biotech hub.

BioVersys AG is committed to advancing healthcare through cutting-edge research and development. As a leader in the field, BioVersys AG continues to drive progress in overcoming antibiotic resistance and improving patient outcomes. We invite the management team of BioVersys AG to create a customized and exclusive company showcase and product listing on our platform.